Abstract Number: PB0424
Meeting: ISTH 2020 Congress
Theme: Coagulation and Natural Anticoagulants » Tissue Factor Pathway
Background: We have routinely used thrombin generation to investigate patients with unclassified bleeding disorder (UBD).
Aims: To investigate haemostatic abnormalities in patients with UBD that had abnormal thrombin generation on at least one occasion.
Methods: Investigation of 13 known UBD patients with thrombin generation and detailed haemostatsic testing was undertaken including TFPI assays but also thrombomodulin and fibrinogen-γ.
Results: 12 females and 1 male were included. No patient had a platelet function disorder or coagulation factor deficiency that explained the bleeding phenotype, though 2 patients had factor deficiencies; a factor X of 0.41IU/ml and a factor XI of 0.51IU/ml. ThromboGenomics revealed variants for these factors but no other abnormalities. Patients were included who previously had either prolonged lag-time or decreased endogenous thrombin potential (ETP) via high dose tissue factor (5pM) or low dose tissue factor (1.5pM) with corn trypsin inhibitor (CTI).. Tissue factor pathway inhibitor (TFPI) activity was significantly increased (p< 0.001; increased in 8 patients) compared to controls and abnormalities in soluble thrombomodulin (2 patients), fibrinogen-γ (1 patient), PAI-1 and tPA (4 patients for each) were seen. Total and free TFPI levels were not increased. Mixing studies of patient plasma with 50:50 normal plasma for thrombin generation via low dose tissue factor failed to correct the ETP consistent with on-going inhibition. Addition of an anti-TFPI antibody corrected thrombin generation to normal levels. TFPI sequencing was unremarkable.
Conclusions: TFPI activity may be increased in a sub-set of UBD patients. Further research studies are warranted in UBD patients for coagulation inhibitor abnormalities.
[Thrombin generation profile of study patients when mixed with normal plasma and anti-TFPI antibody]
[Anticoagulant levels observed between normal volunteers and the patient cohort. TFPI – Tissue Factor Pathway Inhibitor. Shaded – reference range]
To cite this abstract in AMA style:
White D, MacDonald S, Langdown J, Downes K, Thomas W. Anticoagulant Activity in Unclassified Bleeding Disorders [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/anticoagulant-activity-in-unclassified-bleeding-disorders/. Accessed September 21, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/anticoagulant-activity-in-unclassified-bleeding-disorders/